CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 167 enrolled
Drug / intervention
Selumetinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00866177
NCT00866177Phase 2Completed
CompareCT.gov

Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients With BRAF or NRAS Mutated Melanomas

National Cancer Institute (NCI)·interventional·Posted Mar 20, 2009·Updated Aug 11, 2015

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Selumetinib for Recurrent Melanoma and 2 related conditions. Completed, enrolled 167 participants across 1 site.

Detailed Summary

This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 20, 2009
Enrollment StartMar 1, 2009
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 17.3 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Selumetinibdrug

Given orally